

# Resource Summary Report

Generated by [NIF](#) on Sep 10, 2026

## CD19 Antibody, anti-human, VioBlue®, REAfinity™

RRID:AB\_2784030

Type: Antibody

### Proper Citation

Miltenyi Biotec Cat# 130-120-031, RRID:AB\_2784030

### Antibody Information

**URL:** [http://antibodyregistry.org/AB\\_2784030](http://antibodyregistry.org/AB_2784030)

**Proper Citation:** Miltenyi Biotec Cat# 130-120-031, RRID:AB\_2784030

**Target Antigen:** CD19

**Host Organism:** human

**Clonality:** monoclonal

**Antibody Name:** CD19 Antibody, anti-human, VioBlue®, REAfinity™

**Description:** This monoclonal targets CD19

**Target Organism:** human

**Clone ID:** clone REA675

**Antibody ID:** AB\_2784030

**Vendor:** Miltenyi Biotec

**Catalog Number:** 130-120-031

**Record Creation Time:** 20231110T032955+0000

**Record Last Update:** 20260901T020844+0000

### Ratings and Alerts

No rating or validation information has been found for CD19 Antibody, anti-human, VioBlue®, REAfinity™.

No alerts have been found for CD19 Antibody, anti-human, VioBlue®, REAfinity™.

## Data and Source Information

**Source:** [Antibody Registry](#)

## Usage and Citation Metrics

We found 2 mentions in open access literature.

**Listed below are recent publications.** The full list is available at [NIF](#) .

Calaud C, et al. (2026) Enhanced efficacy of a specific HDAC3 inhibitor in combination with 5-azacitidine against diffuse large B-cell lymphoma. Blood neoplasia, 3(2), 100214.

Krug A, et al. (2024) Inhibition of choline metabolism in an angioimmunoblastic T-cell lymphoma preclinical model reveals a new metabolic vulnerability as possible target for treatment. Journal of experimental & clinical cancer research : CR, 43(1), 43.